NCT07221565
Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)
Enrolling by Invitation
PHASE1All AgesInterventionalTreatmentTruway Health, Inc.
~120 participants
Updated 2026-05-22 on ClinicalTrials.gov
What's tested:Low-Frequency Electromagnetic Resonance Therapy (LF-EMR)Sham Resonance Device (Inactive Control)Low-Dose Naltrexone (LDN)
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Autoimmune Flare Frequency
Measured over Baseline to Month 6
Conditions
Where it's being run
1 sites across 1 statesNew York1
Study leadership
- Gavin Solomon, President & CEO · PRINCIPAL_INVESTIGATOR · Truway Health, Inc.
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Change in Autoimmune Flare FrequencyBaseline to Month 6
Number of clinically confirmed autoimmune flare events during the 6-month observation period compared to baseline, using validated disease-specific scoring systems (e.g., SLEDAI for lupus, DAS-28 for rheumatoid arthritis, or EDSS for multiple sclerosis).